FDA Approves RINVOQ as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease
AbbVie announced that the FDA had approved RINVOQ® (upadacitinib) for treating people with moderately to highly active Crohn's disease who have had an unsatisfactory response or intolerance to one or more TNF blockers. This is RINVOQ's sixth FDA approval in rheumatology, dermatology, and gastroenterology, which is now indicated in ulcerative colitis and Crohn's disease.
Crohn's disease is a chronic, systemic disease characterized by inflammation of the gastrointestinal (or digestive) tract, resulting in persistent diarrhea and abdominal pain. It is a progressive disease, w...
